Lonvo-z CRISPR Therapy Wins FDA Priority Review for Swelling Disorder

A milestone that isn't a cure yet

The hype around Intellia Therapeutics' lonvoguran ziclumeran, or lonvo-z, has moved faster than the regulatory process. Claims that the therapy has already "redefined medicine" get ahead of the facts. The drug is not approved. On September 8, 2026, the U.S. Food and Drug Administration accepted Intellia's Biologics License Application (BLA) for lonvo-z in hereditary angioedema (HAE), granted it Priority Review and set a target action date of March 10, 2027.26 The agency also told the company it does not currently plan to convene an advisory committee on the application.219

Still, the development is a real turning point for CRISPR. If the FDA approves lonvo-z, it would be the first in vivo CRISPR-based therapy in the world, meaning the gene editing takes place inside the patient's body rather than in cells removed and edited in a lab. It would also be the only one-time treatment for HAE.26 Lonvo-z now has a regulatory decision date, positive Phase 3 data published in the New England Journal of Medicine, and a clear path to market. In vivo CRISPR has been promised for years, and it has rarely been this close to approval.19

What the Phase 3 trial showed

The application is built mainly on HAELO, a randomized, double-blind, placebo-controlled Phase 3 trial. It enrolled 80 adults and adolescents aged 16 and older with Type I or Type II HAE. Of these, 52 received a single 50 mg intravenous infusion of lonvo-z and 28 received placebo.12 Intellia says enrollment was completed in nine months, which points to strong demand from patients.2

The main result was clear. From week 5 through week 28, the treated group had 87% fewer HAE attacks than the placebo group. The mean monthly attack rate was 0.26 with lonvo-z and 2.10 with placebo (p<0.0001).14 Healio, reporting from the published data, gave a 95% confidence interval of –93% to –78% for that relative reduction.19 The trial also met every key secondary endpoint. The most important for patients: 62% of the lonvo-z group were completely free of both attacks and HAE therapy for the six-month efficacy period, compared with 11% on placebo.14 As of the February 10, 2026 data cutoff, every patient who had received lonvo-z, either at the start or after crossing over from placebo after week 28, was still off long-term preventive therapy.2

Quality-of-life scores improved as well. Treated patients improved by 23.51 points on the Angioedema Quality of Life scale by week 28, compared with 6.47 points on placebo. Intellia notes that a 6-point change is considered clinically meaningful.

The safety data so far are encouraging. Intellia reported that all treatment-emergent adverse events up to the cutoff were mild or moderate, and there were no serious adverse events in the lonvo-z arm.14 The most common events that occurred more often with lonvo-z than placebo were infusion-related reactions, headache, fatigue, back pain and upper respiratory infections.2

How the therapy works

HAE causes unpredictable and sometimes dangerous swelling attacks driven by bradykinin. Lonvo-z uses CRISPR/Cas9 to switch off the KLKB1 gene in the liver. That gene encodes prekallikrein, the precursor of kallikrein. Lowering kallikrein permanently should reduce the bradykinin that causes the swelling.1411 The therapy is given once, as an outpatient infusion.2

The main difference from current care is the one-time dose. Existing prevention for most patients means injections or daily oral drugs taken indefinitely.3 Lonvo-z is meant to change the pathway once rather than suppress it over and over.10 Aleena Banerji of Massachusetts General Hospital, senior author on HAELO, told Healio that approval would change the treatment approach by removing the cumulative burden of long-term preventive therapy for many patients.19

Durability: the evidence so far

The obvious question for any "one-and-done" claim is whether the effect lasts. The earlier data on this are strong. In the Phase 1 portion of the Phase 1/2 study, all 10 patients had a mean 98% reduction in monthly attack rate over up to three years of follow-up. They also went a median of 23 months without attacks or treatment.13 A pooled analysis of 32 patients given the 50 mg dose, with a median follow-up of 12.2 months, found plasma kallikrein reductions of 86% to 96% that held steady, and a mean monthly attack rate of about 0.2 throughout.12

These results are why investigators and analysts are confident. Penn State allergist Timothy Craig called the primary result "groundbreaking." Intellia CEO John Leonard described HAELO as the first Phase III data to fulfill in vivo CRISPR's long-promised potential. Wedbush's base case is approval, citing the 87% attack reduction and the 62% attack-free, therapy-free rate.1

Where the coverage differs

Most reporting agrees on the core facts: the 87% figure, the 62% versus 11% comparison, the March 10, 2027 action date and the lack of a planned advisory committee.23810 There are a few differences worth noting.

First, BioSpace reported an 89% reduction. That figure refers to monthly attacks requiring on-demand treatment, which is a different measure from the headline primary endpoint. Both numbers are probably accurate. Readers should just know that 87% is the primary endpoint result.

Second, some outlets are more cautious than others. NovaPharmaNews points out that accepting a BLA is not the same as approving it, and that Priority Review shortens the review timeline without guaranteeing approval. It also lists unanswered questions: durability past the February 2026 cutoff, possible off-target edits, and whether real-world use prevents dangerous airway attacks.3 The same outlet's tracker widget, however, lists a July 2026 PDUFA date and an oncology category. Both contradict its own article and every other source.3 The correct target date is March 10, 2027.6

Third, timing language has shifted. Intellia's April statements said a U.S. launch could come in the first half of 2027 if the drug is approved.14 Now that a March 10 action date is set, that timeline looks realistic, though it still depends on approval. Archyde notes that without an advisory committee, the outcome depends on the FDA's own review of manufacturing, efficacy and safety data.9

Market and competition

Lonvo-z would not enter an empty market. BioSpace reported that analysts see it as a strong challenger to Ionis Pharmaceuticals, whose HAE drug Dawnzera launched in the U.S. in August. William Blair said that launch had beaten expectations, which it read as a good sign for the HAE market overall. The analysts presented lonvo-z as a different option because it is dosed once, not as a guaranteed replacement for existing drugs. FirstWord's interview with Craig made a similar point: the therapy will disrupt HAE care, but perhaps "not as much as it might have." That suggests chronic therapies are improving and will remain competitive.

The financial side carries its own caution. One analysis noted that Intellia has no approved products and continues to lose money, so the stock may not move much even if approval comes.1 Investors have reacted strongly to clinical news before. Intellia shares rose 23% after detailed HAELO data were presented at the European Academy of Allergy and Clinical Immunology congress.

Why it matters for CRISPR

The significance goes beyond HAE. Lonvo-z already has FDA Orphan Drug and RMAT designations, a U.K. Innovation Passport from the MHRA, PRIME status from the European Medicines Agency, and EU orphan designation.6 The RMAT designation allowed Intellia to submit its application on a rolling basis, starting in April.5 Together, these show regulators on both sides of the Atlantic giving priority to this kind of medicine.

Our view: this is the clearest evidence yet that in vivo CRISPR editing can work as a mainstream treatment, not just as an experiment. The trial was well controlled, the effect was large, the durability data are building, and safety so far has caused no serious problems. A smooth review would show that editing a gene inside the body can pass regulatory review on the same terms as conventional drugs.

The proof is not complete, however. Long-term durability, off-target editing and how patients and payers will view a permanent change compared with reversible chronic therapy are still open questions.3 The decision expected on March 10, 2027 is the real test. Until then, lonvo-z is a strong candidate to change medicine, but it has not yet done so.